

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
THEIS et al.

Examiner: **K.T. Hirianna**

Art Unit: **1633**

Application No.: **10/594419**

Filed: **May 22, 2007**

Title: **Dual-transfected Cells Lines As In Vitro
Screening Tools For Pharmaceutical Compound
Profiling: A Model For Heptobiliary Elimination**

REPLY TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated September 30, 2009, Group 1 is elected. Group 1 contains claims 1-2, 4-9, 27-28, and 30-35 drawn to a mammalian cell. As noted by the Examiner, claim 27 has a typographical error and thus claim 27 and those claims dependent therefrom would comprise Group 5. Thus, Group 1 contains claims 102 and 4-9.

Respectfully submitted,
/Ann Marie Szczepanik/
Ann Marie Szczepanik, Reg. No. 52,267

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-**4757**
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2004/0025 US PCT